Preliminary approaches to early detect the primary hyperparathyroidism from patients with normocalcemia and elevated serum parathyroid hormone levels

Bone ◽  
2008 ◽  
Vol 43 ◽  
pp. S101-S102
Author(s):  
Lin Zhao ◽  
Jianmin Liu ◽  
Minjia Zhang ◽  
Guang Ning
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Elevated Serum ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels

Falsely Elevated Serum Parathyroid Hormone Levels due to Immunoglobulin G in a Patient with Idiopathic Hypoparathyroidism*

1991 ◽  
Vol 72 (1) ◽  
pp. 217-222 ◽  
Author(s):  
KEIZO KASONO ◽  
KANJI SATO ◽  
TOMOHARU SUZUKI ◽  
EIJI OHMURA ◽  
REIKO DEMURA ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Immunoglobulin G ◽  
Elevated Serum ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels

Patients with Elevated Serum Parathyroid Hormone Levels after Parathyroidectomy: Showing Signs of Decreased Peripheral Parathyroid Hormone Sensitivity

2003 ◽  
Vol 27 (2) ◽  
pp. 212-215 ◽  
Author(s):  
Erik Nordenström ◽  
Johan Westerdahl ◽  
Anders Isaksson ◽  
Pia Lindblom ◽  
Anders Bergenfelz
Keyword(s):  
Parathyroid Hormone ◽  
Elevated Serum ◽  
Serum Parathyroid Hormone ◽  
Hormone Sensitivity ◽  
Hormone Levels

Intact parathyroid hormone levels and primary hyperparathyroidism

2017 ◽  
pp. 1-5 ◽  
Author(s):  
Haidar Al-Hraishawi ◽  
Peter J. Dellatore ◽  
Xinjiang Cai ◽  
Xiangbing Wang
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Intact Parathyroid Hormone ◽  
Hormone Levels

scholarly journals A novel CASR variant in a family with familial hypocalciuric hypercalcaemia and primary hyperparathyroidism

2020 ◽  
Vol 2020 ◽  
Author(s):  
Satyanarayana V Sagi ◽  
Hareesh Joshi ◽  
Jamie Trotman ◽  
Terence Elsey ◽  
Ashwini Swamy ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Organ Damage ◽  
Urinary Calcium ◽  
Interesting Case ◽  
List Type ◽  
Loss Of Function ◽  
Clearance Ratio ◽  
Hormone Levels ◽  
Severe Hypercalcaemia

Summary Familial hypocalciuric hypercalcaemia (FHH) is a dominantly inherited, lifelong benign disorder characterised by asymptomatic hypercalcaemia, relative hypocalciuria and variable parathyroid hormone levels. It is caused by loss-of-function pathogenic variants in the calcium-sensing receptor (CASR) gene. Primary hyperparathyroidism (PHPT) is characterised by variable hypercalcaemia in the context of non-suppressed parathyroid hormone levels. Unlike patients with FHH, patients with severe hypercalcaemia due to PHPT are usually symptomatic and are at risk of end-organ damage affecting the kidneys, bone, heart, gastrointestinal system and CNS. Surgical resection of the offending parathyroid gland(s) is the treatment of choice for PHPT, while dietary adjustment and reassurance is the mainstay of management for patients with FHH. The occurrence of both FHH and primary hyperparathyroidism (PHPT) in the same patient has been described. We report an interesting case of FHH due to a novel CASR variant confirmed in a mother and her two daughters and the possible coexistence of FHH and PHPT in the mother, highlighting the challenges involved in diagnosis and management. Learning points: Familial hypocalciuric hypercalcaemia (FHH) and primary hyperparathyroidism (PHPT) can coexist in the same patient. Urinary calcium creatinine clearance ratio can play a role in distinguishing between PHPT and FHH. Genetic testing should be considered in managing patients with PHPT and FHH where the benefit may extend to the wider family. Family segregation studies can play an important role in the reclassification of variants of uncertain significance. Parathyroidectomy has no benefit in patients with FHH and therefore, it is important to exclude FHH prior to considering surgery. For patients with coexisting FHH and PHPT, parathyroidectomy will reduce the risk of complications from the severe hypercalcaemia associated with PHPT.

scholarly journals Famotidine Reduces Serum Parathyroid Hormone Levels in Uremic Patients

Nephron ◽  
1991 ◽  
Vol 59 (2) ◽  
pp. 333-333
Author(s):  
Nurol Arik ◽  
Turgay Arinsoy ◽  
Murat Sayin ◽  
Ilgar Taşdemir ◽  
Ünal Yasavul ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Serum Parathyroid Hormone ◽  
Hormone Levels ◽  
Uremic Patients

Parathyroid hormone-related peptide, measured by a midmolecule radioimmunoassay, in various hypercalcaemic and normocalcaemic conditions

1992 ◽  
Vol 127 (4) ◽  
pp. 294-300 ◽  
Author(s):  
Elisabet Bucht ◽  
Anders Eklund ◽  
Göran Toss ◽  
Rolf Lewensohn ◽  
Barbro Granberg ◽  
...  
Keyword(s):  
Parathyroid Hormone ◽  
Primary Hyperparathyroidism ◽  
Elevated Serum ◽  
Skeletal Metastases ◽  
Endocrine Diseases ◽  
Related Peptide ◽  
Silica Cartridge ◽  
The Subject ◽  
Parathyroid Hormone Related Peptide ◽  
Made In

The diagnosis of humoral hypercalcaemia of malignancy often presents considerable clinical problems. We have studied parathyroid hormone-related peptide (PTHrP) in serum from patients with humoral hypercalcaemia of malignancy (N=22), hypercalcaemia of malignancy with skeletal metastases(1 7), histologically confirmed primary hyperparathyroidism (21) and hypercalcaemic patients with various benign diseases (9). PTHrP measurements were also made in normocalcaemic patients with various malignancies (23), endocrine diseases (13), sarcoidosis (22) and chronic renal failure (17). PTHrP was measured by a novel radioimmunoassay using rabbit antibodies directed towards the midregion of the molecule. Immuno- or silica cartridge extraction of serum before radioimmunoassay enabled us to measure PTHrP in all samples, which may add further information about circulating forms of PTHrP. PTHrP was clearly elevated in patients with humoral hypercalcaemia of malignancy (5.0±4.7 pmol/l) (mean±sd, N=12) and when the kidney function was impaired (4.0±0.9 pmol/l) (N=15) (silica cartridge extraction), whether the subject was hyperalcaemic or not. Some patients with endocrine diseases, including two with primary hyperparathyroidism, had slightly elevated serum PTHrP concentrations, while they were normal in sarcoidosis. In healthy subjects the levels were 1.1±0.5 pmol/1 (N= 15) after immunoextraction and 0.8±0.2 pmol/l(N= 33) after silica cartridge extraction.

Sign in / Sign up

Export Citation Format

Share Document